Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastric and Gastroesophageal Junction Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06310473
What this trial is testing

Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial

Who this might be right for
Gastric CancerEsophagogastric Junction Cancer
Nanfang Hospital, Southern Medical University 30
Not applicableNot Yet RecruitingNCT07662005
What this trial is testing

Objective Sleep Characteristics and Neoadjuvant Immunotherapy Response in Gastric/GEJ Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaSleep+1 more
West China Second University Hospital 120
Testing effectiveness (Phase 2)Ended earlyNCT04933227
What this trial is testing

Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Who this might be right for
Stomach NeoplasmsGastric CancerGastroesophageal Junction Adenocarcinoma
Hoffmann-La Roche 29
Early research (Phase 1)Ended earlyNCT06714617
What this trial is testing

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Who this might be right for
Breast Cancer Stage IIIHER2-positive Metastatic Breast CancerUnresectable Breast Carcinoma+11 more
SystImmune Inc. 3
Not applicableWithdrawnNCT04520867
What this trial is testing

STRENGTH Expansion

Who this might be right for
Esophageal CancerGastroesophageal Junction Cancer
University of Colorado, Denver
Early research (Phase 1)Ended earlyNCT05229900
What this trial is testing

SGN-ALPV in Advanced Solid Tumors

Who this might be right for
Ovarian NeoplasmsEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung+4 more
Seagen Inc. 43
Testing effectiveness (Phase 2)Looking for participantsNCT07102901
What this trial is testing

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

Who this might be right for
Advanced Gastric CancerMetastatic Gastric CancerGastroesophageal Junction Adenocarcinoma
Jiangsu HengRui Medicine Co., Ltd. 351
Early research (Phase 1)UnknownNCT03847168
What this trial is testing

KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer

Who this might be right for
Breast CancerGastric/Gastroesophageal Junction Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 22
Testing effectiveness (Phase 2)Looking for participantsNCT07110571
What this trial is testing

A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer

Who this might be right for
Gastric CancerGastroesophageal-junction Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 200
Testing effectiveness (Phase 2)Looking for participantsNCT05482893
What this trial is testing

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Who this might be right for
Gastric or Gastroesophageal Junction AdenocarcinomaPancreatic Ductal AdenocarcinomaBiliary Tract Cancer (BTC)
Phanes Therapeutics 258
Testing effectiveness (Phase 2)Active Not RecruitingNCT06939452
What this trial is testing

A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression

Who this might be right for
Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Yongxu Jia 37
Large-scale testing (Phase 3)Active Not RecruitingNCT03653507
What this trial is testing

Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Early research (Phase 1)Looking for participantsNCT06293898
What this trial is testing

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Who this might be right for
Endometrial CancerCervical CancerOvarian Cancer+7 more
SystImmune Inc. 280
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07685704
What this trial is testing

Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
Zhifeng Zhao, PhD 46
Testing effectiveness (Phase 2)Study completedNCT02689284
What this trial is testing

Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Gastric CancerStomach CancerEsophageal Cancer
MacroGenics 95
Early research (Phase 1)Ended earlyNCT02862535
What this trial is testing

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Adenocarcinoma
Gilead Sciences 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT03448835
What this trial is testing

Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)

Who this might be right for
Stomach CancerGastro Esophageal Junction Cancer
The Netherlands Cancer Institute 20
Testing effectiveness (Phase 2)UnknownNCT05346874
What this trial is testing

Neoadjuvant TACiE in Locally Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
Shanghai Zhongshan Hospital 37
Not applicableUnknownNCT03626610
What this trial is testing

Prehabilitation of Patients With oEsophageal Malignancy Undergoing Peri-operative Treatment

Who this might be right for
Oesophageal AdenocarcinomaChemotherapy EffectSurgery
Guy's and St Thomas' NHS Foundation Trust 66
Testing effectiveness (Phase 2)UnknownNCT05019794
What this trial is testing

Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaSolid Tumor
LianBio LLC 80
Next Page
507